Nitazoxanide: a first-in-class broad-spectrum antiviral agent
- PMID: 25108173
- PMCID: PMC7113776
- DOI: 10.1016/j.antiviral.2014.07.014
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
Abstract
Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. A Phase 2b/3 clinical trial recently published in The Lancet Infectious Diseases found that oral administration of nitazoxanide 600mg twice daily for five days reduced the duration of clinical symptoms and reduced viral shedding compared to placebo in persons with laboratory-confirmed influenza. The same study also suggested a potential benefit for subjects with influenza-like illness who did not have influenza or other documented respiratory viral infection. From a chemical perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides. These small-molecule drugs target host-regulated processes involved in viral replication. Nitazoxanide is orally bioavailable and safe with extensive post-marketing experience involving more than 75 million adults and children. A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clinical development for the treatment of influenza. Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors. It is synergistic with neuraminidase inhibitors, and combination therapy with oseltamivir is being studied in humans as part of ongoing Phase 3 clinical development. Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, coronavirus, rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays. Clinical trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C. Ongoing and future clinical development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever.
Keywords: Antiviral therapy; Broad-spectrum; Influenza; Nitazoxanide; Thiazolides.
Copyright © 2014 The Author. Published by Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials.Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. doi: 10.1128/AAC.00222-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32312780 Free PMC article.
-
Thiazolides: a new class of antiviral drugs.Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. doi: 10.1517/17425250902988487. Expert Opin Drug Metab Toxicol. 2009. PMID: 19442032 Review.
-
Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level.J Biol Chem. 2009 Oct 23;284(43):29798-808. doi: 10.1074/jbc.M109.029470. Epub 2009 Jul 28. J Biol Chem. 2009. PMID: 19638339 Free PMC article.
-
Therapeutic potential of salicylamide derivatives for combating viral infections.Med Res Rev. 2023 Jul;43(4):897-931. doi: 10.1002/med.21940. Epub 2023 Mar 10. Med Res Rev. 2023. PMID: 36905090 Free PMC article. Review.
-
Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.Antimicrob Agents Chemother. 2015 Feb;59(2):1061-9. doi: 10.1128/AAC.03947-14. Epub 2014 Dec 1. Antimicrob Agents Chemother. 2015. PMID: 25451059 Free PMC article.
Cited by
-
In vitro synergistic antiviral activity of repurposed drugs against enterovirus 71.Arch Virol. 2024 Jul 30;169(8):169. doi: 10.1007/s00705-024-06097-1. Arch Virol. 2024. PMID: 39078431
-
In silico molecular screening of bioactive natural compounds of rosemary essential oil and extracts for pharmacological potentials against rhinoviruses.Sci Rep. 2024 Jul 29;14(1):17426. doi: 10.1038/s41598-024-68450-3. Sci Rep. 2024. PMID: 39075176 Free PMC article.
-
Generation of rescued Japanese encephalitis virus genotype 1 from infectious full-size clone using reverse genetics.Heliyon. 2024 Jun 17;10(13):e33142. doi: 10.1016/j.heliyon.2024.e33142. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39040327 Free PMC article.
-
Antiviral Chemotherapy in Avian Medicine-A Review.Viruses. 2024 Apr 12;16(4):593. doi: 10.3390/v16040593. Viruses. 2024. PMID: 38675934 Free PMC article. Review.
-
Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms.Appl Mater Today. 2021 Mar;22:100887. doi: 10.1016/j.apmt.2020.100887. Epub 2020 Dec 5. Appl Mater Today. 2021. PMID: 38620577 Free PMC article. Review.
References
-
- Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet. 2002;360:1375–1380. - PubMed
-
- Ashiru O., Howe J.D., Butters T.D. Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca2+ stores. Virology. 2014;462–463:135–148. - PubMed
-
- Baishanbo A., Gargala G., Duclos C., François A., Rossignol J.F., Ballet J.J., Favennec L. Efficacy of nitazoxanide and paromomycin on biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J. Antimicrob. Chemother. 2006;57:353–355. - PubMed
-
- Belardo, G., La Frazia, S., Cenciarelli, O., Carta, S., Rossignol, J.F., Santoro, M.G., 2011. Nitazoxanide, a novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors. Poster presented at: 49th Infectious Disease Society of America Annual Meeting, Oct 20–23, 2011, Boston, Massachusetts. https://idsa.confex.com/idsa/2011/webprogram/Paper31075.html.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical